By Dr. Anam Kamal Ascension Providence Hospital TROPION-Lung01: A randomized, phase-3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated
MoreWe are thrilled to announce that we will be providing comprehensive coverage of the European Society for Medical Oncology (ESMO) conference taking place in Madrid, Spain from October 20 to 24, 2023. Our dedicated Cancer News Editorial team, including Dr. Lei Deng and contributing expert Dr. Anam Kamal, will be on the ground to bring you in-depth reports on the pioneering research, cutting-edge treatments, and collaborative dialogues unveiled during this important scientific meeting.
By Dr. Anam Kamal Ascension Providence Hospital TROPION-Lung01: A randomized, phase-3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated
MoreESMO 2023 Update – KEYNOTE-671: The First Perioperative Immunotherapy Clinical Trial in Non-Small Cell Lung Cancer Improving Overall Survival Author: Lei Deng,
MoreESMO 2023 Update – MARIPOSA: Amivantamab + Lazertinib Improves Progression-Free Survival Compared to Osimertinib in EGFR-Mutated, Treatment-Naïve Non-Small Cell Lung Cancer
MoreESMO 2023 Update – ALINA: Adjuvant Alectinib Improves Disease-Free Survival in Resected Early-Stage Non-Small Cell Lung Cancer Author: Lei Deng, MD Assistant
MoreLIBRETTO-431: Randomized phase III study of selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive advanced NSCLC Author: Dr. Anam Kamal Selpercatinib is a
MoreESMO 2023 Update – CheckMate 77T: Another Phase 3 Trial of Perioperative Immunotherapy Improving Event-Free Survival for Resectable Stage II-III Non-Small Cell
More